ZEISS Vision Care has announced the acquisition of an intellectual property (IP) portfolio from Mitsui Chemicals (MCI) that includes a suite of patents for electronically focusing eyewear.
The company said the move reinforced ZEISS’ commitment to advancing technology in the eyeglass lens industry, opening new opportunities for electro-active lenses and spectacle frames.
MCI’s IP portfolio includes several patents for electric functionality in tailored lenses and frame electronics. ZEISS said this investment aligns with the company’s mission to enhance user experience and push the boundaries of technological innovation within the eyewear sector.
While financial details of the transaction remain undisclosed, ZEISS said the patents would make invaluable contributions to its ongoing research and development initiatives as well as to its licensing business.
“We are pleased to announce the acquisition of this exceptional IP portfolio from Mitsui Chemicals. This strategic move reinforces our commitment to remain at the forefront of technological advancements in the eyeglass lens industry,” Dr Michael Hentschel, global head of technology and innovation at ZEISS Vision Care, said.
“The acquired patents complement our existing capabilities and will play a pivotal role in shaping the future of eyeglass lens solutions for consumers worldwide.”
More reading
Sigo Eyecare opening Australia’s first ZEISS VISION CENTRE concept store
ZEISS wraps up successful 2023 RANZCO Congress
ZEISS now offering complete Kids Portfolio